Dr. Larry Snyder serves as Vice President of Medicinal Chemistry at Arvinas. Dr. Snyder joined Arvinas in 2015 after more than 20 years in the biopharmaceutical industry.
Prior to joining Arvinas, Dr. Snyder worked at Bristol-Myers Squibb where he led programs in the antibacterial, antiviral, and neuroscience therapeutic areas. Under Dr. Snyder leadership, the potential for discovering a novel treatment and cure for hepatitis C was realized, leading to the marketed novel NS5A protein inhibitor, Daklinza®.
At Arvinas, Dr. Snyder led the chemistry effort resulting in the discovery of ARV-110 and ARV-776,, Arvinas’ orally bioavailable novel PROTAC® protein degraders for the treatment of men with metastatic castration resistant prostate cancer.
Dr. Snyder received his Ph.D. from Colorado State University under the direction of the late Albert I. Meyers and did his post-doctoral training at Memorial Sloan Kettering Cancer Center under Samuel J. Danishefsky.